Ambrx Biopharma Inc
AMAM
AMAM was delisted on the 6th of March, 2024.
44 hedge funds and large institutions have $568M invested in Ambrx Biopharma Inc in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 13 closing their positions.
277% more call options, than puts
Call options by funds: $17.6M | Put options by funds: $4.66M
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
5% more funds holding
Funds holding: 42 → 44 (+2)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
28% less capital invested
Capital invested by funds: $789M → $568M (-$220M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$32.6M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$25M |
| 3 |
CC
Commodore Capital
New York
|
+$4.68M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.19M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$3.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$37.3M |
| 2 |
AG
Artal Group
Luxembourg
|
-$11.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.12M |
| 4 |
Holocene Advisors
New York
|
-$5.82M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.76M |
AMAM Hedge Fund Activity: Q3 2023 in Review
44 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q3 2023, worth a combined $568M — down 28% from $789M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AMAM positions and 13 closed out — a net gain of 3 holders — while 17 added to existing stakes and 7 trimmed.
The largest buyer was Federated Hermes, opening a new position worth an estimated $32.6M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $37.3M sold.
- 44 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q3 2023, up from 42 in Q2 2023.
- Funds reported $568M of Ambrx Biopharma Inc stock for Q3 2023, down 28% quarter-over-quarter.
- 16 funds opened new Ambrx Biopharma Inc positions in Q3 2023 and 13 closed out, a net change of +3 holders.
- The largest Ambrx Biopharma Inc buyer in Q3 2023 was Federated Hermes, an estimated $32.6M added.
- The largest Ambrx Biopharma Inc seller in Q3 2023 was Farallon Capital Management, an estimated $37.3M sold.
Based on aggregated 13F filings for Q3 2023.